0001140361-15-014742.txt : 20150408
0001140361-15-014742.hdr.sgml : 20150408
20150408164748
ACCESSION NUMBER: 0001140361-15-014742
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150407
FILED AS OF DATE: 20150408
DATE AS OF CHANGE: 20150408
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1035 O?BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 1035 O?BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blumenkranz Mark S.
CENTRAL INDEX KEY: 0001614869
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 15759519
MAIL ADDRESS:
STREET 1: C/O AVALANCHE BIOTECHNOLOGIES, INC.
STREET 2: 1035 O'BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
doc1.xml
FORM 4
X0306
4
2015-04-07
0
0001501756
Avalanche Biotechnologies, Inc.
AAVL
0001614869
Blumenkranz Mark S.
C/O AVALANCHE BIOTECHNOLOGIES, INC.
1035 O'BRIEN DRIVE, SUITE A
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2015-04-07
4
S
0
21774
38.5874
D
624215
D
Common Stock
2015-04-07
4
S
0
726
39.0603
D
623489
D
Common Stock
2015-04-08
4
S
0
2500
39.9363
D
620989
D
Common Stock
2015-04-07
4
S
0
968
38.5875
D
11563
I
See Footnote
Common Stock
2015-04-07
4
S
0
32
39.0608
D
11531
I
See Footnote
Common Stock
2015-04-07
4
S
0
968
38.5875
D
11563
I
See Footnote
Common Stock
2015-04-07
4
S
0
32
39.0608
D
11531
I
See Footnote
Common Stock
2015-04-07
4
S
0
968
38.5875
D
11563
I
See Footnote
Common Stock
2015-04-07
4
S
0
32
39.0608
D
11531
I
See Footnote
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
This transaction was executed in multiple trades in prices ranging from $38.02 to $39.00, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $39.025 to $39.16, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $39.90 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares are held directly by the Carla Helene Blumenkranz Irrevocable Trust.
The shares are held directly by the Erik Davis Blumenkranz Irrevocable Trust.
The shares are held directly by the Scott Aubrey Blumenkranz Irrevocable Trust.
/s/ Hans Hull, Attorney-in-Fact for Mark S. Blumenkranz
2015-04-08